Immunovia AB (publ) is a leading company in the field of immunodiagnostic testing for diseases such as cancer. It is known for its commitment to innovation, accuracy, and quality. The company's corporate philosophy revolves around leveraging its expertise in biomarker-based diagnostics to provide enhanced patient care and contribute to early disease detection. Immunovia AB (publ) also values collaboration with healthcare professionals, researchers, and strategic partners to drive advancements in diagnostics. By focusing on cutting-edge technology and a patient-centric approach, Immunovia AB (publ) aims to make a significant impact in the field of healthcare and improve outcomes for patients worldwide.

Immunovia AB (publ) is primarily present in Sweden, where it is headquartered.

Immunovia AB (publ) has achieved significant milestones in its journey. The company successfully developed and commercialized IMMray™, a unique technology platform capable of detecting early-stage cancer and autoimmune diseases. Immunovia AB (publ) has also formed strategic collaborations with key players in the healthcare industry to advance its diagnostic solutions. Moreover, the company received regulatory approvals and certifications, enabling the launch of its products in various markets. Immunovia AB (publ) continues to make strides in advancing precision medicine through its innovative approach and commitment to improving early detection and patient outcomes.

Immunovia AB (publ) is a renowned biotechnology company specializing in early cancer diagnosis and prognosis using blood-based biomarker signatures. Established in 2007, the Swedish-based company has made significant advancements in detecting and predicting various types of cancer, focusing primarily on pancreatic cancer, autoimmune diseases, and other malignancies. With a robust team of experts and groundbreaking technologies, Immunovia is dedicated to offering accurate, reliable, and non-invasive diagnostic solutions that can revolutionize the field of cancer diagnostics. Through extensive research and collaborations, Immunovia aims to improve patient outcomes and contribute to advancements in personalized medicine.

The main competitors of Immunovia AB (publ) in the market include companies like Roche Holding AG, Johnson & Johnson, and Abbott Laboratories.

Immunovia AB (publ) primarily operates in the healthcare and biotechnology industries.

The business model of Immunovia AB (publ) is centered around the development and commercialization of innovative immunological diagnostic tests. The company focuses on the early diagnosis and prognosis of complex diseases, with a particular emphasis on cancer. Immunovia's proprietary technology platform, IMMray™, enables the detection and analysis of complex patterns in blood samples, allowing for the identification and prediction of diseases at an early stage. Through collaboration with healthcare providers and strategic partnerships, Immunovia aims to improve patient outcomes by providing accurate and reliable diagnostic tools.

De Immunovia AB (publ) K/W is 0,36.

De Immunovia AB (publ) KUV is 0,19.

De AlleAktien Kwaliteitsscore voor Immunovia AB (publ) is 6/10.

De verwachte Immunovia AB (publ) omzet is 628,22 mln. SEK.

De verwachte Immunovia AB (publ) winst is 320,07 mln. SEK.

Immunovia AB (publ) is a biotechnology company specializing in the development of diagnostic tests for the early detection of cancer and autoimmune diseases. The company's business model is to utilize its proprietary technologies and patents to develop and market innovative diagnostic products. The company specializes in the development of blood-based tests for detecting biomarkers that indicate various types of cancer, including pancreatic cancer, colorectal cancer, breast cancer, lung cancer, and prostate cancer. Immunovia's main product is a test called IMMray PanCan-d, specifically developed for the detection of pancreatic cancer. It utilizes a technology called protein array-based diagnostics, which analyzes antibodies in the blood. The test is capable of detecting cancer cells at a very early stage and has the potential to significantly improve patient survival rates due to its precision and effectiveness. Immunovia has also partnered with a global pharmaceutical company to bring its technology to market and commercialize it. The company plans to market its tests to both physicians and consumers and has already secured distribution agreements with partners in Europe, Asia, and the USA. In addition to cancer diagnostics, Immunovia has also developed tests for the detection of autoimmune diseases such as lupus, rheumatoid arthritis, and Sjögren's syndrome. These tests utilize similar technologies to the cancer diagnostics products and are also focused on antibodies in the blood. The accuracy of test results and the potential to detect diseases at an early stage could be groundbreaking and change the way autoimmune diseases are diagnosed. In addition to its diagnostic products, Immunovia is working on new technologies and products to further expand its business. This includes innovative methods for processing blood samples and artificial intelligence systems to improve the interpretation of test results. The goal of Immunovia is to revolutionize the diagnosis and treatment of cancer and autoimmune diseases, thereby improving the lives of patients. The company utilizes its extensive experience in researching and developing diagnostic tests, as well as its in-depth knowledge in the field of biotechnology and medical analysis. With its superior technology, wide product portfolio, and growing global presence, Immunovia could play a significant role in the prevention and early detection of cancer and autoimmune diseases in the coming years.

Immunovia AB (publ) keert een dividend van 0 SEK uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Immunovia AB (publ) of het bedrijf keert geen dividend uit.

De ISIN van Immunovia AB (publ) is SE0006091997.

Het WKN van Immunovia AB (publ) is A2AG0F.

De ticker van Immunovia AB (publ) is IMMNOV.ST.

Binnen de laatste 12 maanden betaalde Immunovia AB (publ) een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Immunovia AB (publ) naar verwachting een dividend van 0 SEK betalen.

De dividendrendement van Immunovia AB (publ) is momenteel .

Immunovia AB (publ) betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Immunovia AB (publ) betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 SEK verwacht. Dit komt overeen met een dividendrendement van 0 %.

Immunovia AB (publ) wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Immunovia AB (publ) van 2-8-2024 ter hoogte van 0 SEK te ontvangen, moest je het aandeel voor de ex-datum op 2-8-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 2-8-2024.

In het jaar 2023 heeft Immunovia AB (publ) 0 SEK aan dividenden uitgekeerd.

De dividenden van Immunovia AB (publ) worden in SEK uitgekeerd.